Monday, June 15, 2026

RISING FROM THE DEEP : North Korea’s New “Super-Destroyer” Ambitions Beyond The Strategic Intent

North Korea plans to build an 8,000-ton destroyer to enhance naval power, responding to South Korea's military advancements.

EV Stocks Mixed as Tesla Falls, Rivian and Nikola Surge

EV stocks showed mixed results; Tesla and Lucid fell while Rivian and Nikola gained, highlighting market volatility and competition.

S-OIL’s Shaheen Project Hits 60% Milestone, Installs Record-Breaking Tower

S-OIL has installed the largest propylene separation tower in South Korea, marking progress in the Shaheen project, vital for petrochemical production.

Tag: Celltrion

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

Celltrion Expands AI Integration Strategy to Strengthen Global Pharmaceutical Competitiveness

Celltrion is enhancing its global competitiveness by integrating AI into drug development, manufacturing, and administration.

Celltrion’s Zymfentra Just Hit a New U.S. Prescription Record and the Growth Looks Serious

Celltrion's Zymfentra treatment saw a 185% surge in U.S. prescriptions, driven by effective marketing and reimbursement strategies.

A 90-Minute Cancer Infusion Could Soon Be Cut to 5 Minutes—and Celltrion Wants to Lead It

Celltrion has applied for EMA approval of Herzuma SC, a new breast cancer treatment, enhancing drug delivery and patient convenience.

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Celltrion sees prescription growth for key products in Europe, raises expectations for high-margin new drugs

Celltrion's cancer and autoimmune disease treatments are achieving stable growth in Europe, expanding their market influence.

How is Omlyclo Revolutionizing Allergy Treatment in Europe: Key Successes and Insights

Celltrion's Omlyclo treatment is rapidly gaining market share in Europe, winning tenders and expanding prescriptions across multiple countries.

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

Celltrion Launches Omlyclo in Brazil: How This First Mover is Revolutionizing Autoimmune Treatment

Celltrion launched Omlyclo in Brazil, aiming to boost market penetration and strengthen ties with local medical professionals.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.